ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Jardiance — Outside U.S. revenue by Quarter
Jardiance — Outside U.S. revenue ($M) ($M)
Eli Lilly Jardiance — Outside U.S. revenue: $615M in Q2 2026, up 99.7% from a year earlier.
Latest, Q2 2026
615
Period ended Jun 30, 2026
Change on a year earlier
+99.7%
308 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Eli Lilly Jardiance — Outside U.S. revenue ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-jardiance-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.